Levin Capital Strategies L.P. Has $886,000 Stake in Aura Biosciences, Inc. (NASDAQ:AURA)

Levin Capital Strategies L.P. raised its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 23.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 100,000 shares of the company’s stock after purchasing an additional 18,905 shares during the period. Levin Capital Strategies L.P. owned approximately 0.26% of Aura Biosciences worth $886,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in the stock. Regency Capital Management Inc. DE boosted its stake in Aura Biosciences by 33.8% during the 4th quarter. Regency Capital Management Inc. DE now owns 704,974 shares of the company’s stock valued at $6,246,000 after purchasing an additional 177,996 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Aura Biosciences by 52.0% in the 4th quarter. SG Americas Securities LLC now owns 19,140 shares of the company’s stock worth $170,000 after buying an additional 6,546 shares during the last quarter. Exchange Traded Concepts LLC boosted its stake in shares of Aura Biosciences by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 14,899 shares of the company’s stock worth $132,000 after buying an additional 3,778 shares during the last quarter. Decheng Capital Management III Cayman LLC boosted its stake in shares of Aura Biosciences by 296.5% in the 3rd quarter. Decheng Capital Management III Cayman LLC now owns 1,163,123 shares of the company’s stock worth $10,433,000 after buying an additional 869,790 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its stake in shares of Aura Biosciences by 6.1% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 2,875,000 shares of the company’s stock worth $25,789,000 after buying an additional 165,000 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Price Performance

Shares of NASDAQ AURA traded up $0.09 during midday trading on Thursday, reaching $7.74. The company’s stock had a trading volume of 47,271 shares, compared to its average volume of 164,317. Aura Biosciences, Inc. has a 12-month low of $5.99 and a 12-month high of $13.50. The firm has a 50 day moving average price of $7.87 and a 200-day moving average price of $8.20.

Aura Biosciences (NASDAQ:AURA) last announced its earnings results on Wednesday, March 27th. The company reported ($0.50) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.11). On average, equities analysts anticipate that Aura Biosciences, Inc. will post -2.02 EPS for the current year.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.